Biotekhnologiya, том 37, издание 4, номера страниц: 32-42

Obtaining and Purification of Recombinant Domain III of Human Alpha-Fetoprotein

Mollaev M.D. 1
, 
Zabolotskii A.I. 2
, 
Mazalev D.A. 3
, 
Gorokhovets N.V. 4
, 
Sokol M.B. 5
, 
Mollaeva M.R. 5
, 
Fomicheva M.V. 5
, 
Pshenichnikova A.B. 3
, 
Nikolskaya E.D. 6
1
 
2
 
3
 
4
 
5
 
6
 
Тип документа: Journal Article
Дата публикации: 2021-01-24
Издатель: State Research Institute for Genetics and Selection of Industrial Microorganisms
Название журнала: Biotekhnologiya
Квартиль по SCImago: Q4
Квартиль по Web of Science: —
Импакт-фактор 2021: —
ISSN: 02342758, 25002341
Applied Microbiology and Biotechnology
Biotechnology
Ecology
Краткое описание
Previous studies have demonstrated the applicability of alpha-fetoprotein or its receptor-binding domain fused to the 6-histidine tag at the C-terminus (rAFP3D-His6) as vectors for targeted delivery of antitumor agents. This tag is undesirable for further preclinical trials. Therefore, we designed a recombinant protein rAFP3D without any affine tags, and accessed its functional activity. The protein was produced as inclusion bodies in Escherichia coli BL21 (DE3) cells. Optimal conditions for washing inclusion bodies and refolding the target protein were selected. We used a saturated solution of (NH4)2SO4 as the primary purification step to precipitate the main fraction of protein admixtures. The second purification step included hydrophobic chromatography using butyl-cellulose. The identity of the protein sequence was confirmed by tandem mass spectrometry. Circular dichroism demonstrated the authenticity of the secondary structure. Fluorescently labeled rAFP3D actively penetrated into MCF-7 tumor cells. These results indicate that rAFP3D can be used for targeted drug delivery. Key words: alpha-fetoprotein, receptor-binding domain, recombinant protein, MALDI-MS, HPLC, drug delivery system Funding - The project was supported with Russian Foundation for Basic Research (project no. 18-29-09022/20).
Пристатейные ссылки: 24
Цитируется в публикациях: 2
По дате
По цитируемости
Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer
Lin B., Wang Q., Liu K., Dong X., Zhu M., Li M.
Q1 Frontiers in Oncology,  2021,  цитирований: 3 , 
Open Access
Open access
Cellular internalization of targeted and non-targeted delivery systems for contrast agents based on polyamidoamine dendrimers
Sokol M.B., Faustova M.R., Nikolskaya E.D., Zhunina O.A., Fomicheva M.V., Petrov R.V., Yabbarov N.G.
Q3 Russian Chemical Bulletin,  2020,  цитирований: 4
Cancer statistics, 2020
Siegel R.L., Miller K.D., Jemal A.
Q1 Ca-A Cancer Journal for Clinicians,  2020,  цитирований: 11265
[The public opinion about health care: the main factors of increasing satisfaction of population with medical care].
Iu. V. M., T. A. S., I. M. S., V. O. S., A. L. L., A. Iu. M.
Q4 Problemy sotsial'noi gigieny i istoriia meditsiny / NII sotsial'noi gigieny, ekonomiki i upravleniia zdravookhraneniem im. N.A. Semashko RAMN, AO 'Assotsiatsiia 'Meditsinskaia literatura',  2019,  цитирований: 2
Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate
Mollaev M., Gorokhovets N., Nikolskaya E., Faustova M., Zabolotsky A., Zhunina O., Sokol M., Zamulaeva I., Severin E., Yabbarov N.
Q1 International Journal of Pharmaceutics,  2019,  цитирований: 14 , 
Open Access
Open access
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Feng Y., Spezia M., Huang S., Yuan C., Zeng Z., Zhang L., Ji X., Liu W., Huang B., Luo W., Liu B., Lei Y., Du S., Vuppalapati A., Luu H.H., et. al.
Q1 Genes and Diseases,  2018,  цитирований: 222 , 
Open Access
Open access
Recombinant alpha-fetoprotein receptor-binding domain co-expression with polyglutamate tags facilitates in vivo folding in E. coli.
Mollaev M., Gorokhovets N., Nikolskaya E., Faustova M., Zabolotsky A., Sokol M., Tereshenko O., Zhunina O., Shvets V., Severin E., Yabbarov N.
Q3 Protein Expression and Purification,  2018,  цитирований: 4
Development of target delivery system based on actinomycin class drugs and recombinant alpha-fetoprotein
Nikolskaya E.D., Zhunina O.A., Yabbarov N.G., Shvets V.I., Krugliy B.I., Severin E.S.
Q3 Doklady Biochemistry and Biophysics,  2017,  цитирований: 5
The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins
Mizejewski G.J.
Q2 Tumor Biology,  2016,  цитирований: 6 , 
Open Access
Open access
New approaches to targeted drug delivery to tumour cells
Severin E.S.
Q1 Russian Chemical Reviews,  2015,  цитирований: 13
Pathogenesis, prevention, diagnosis and treatment of breast cancer.
Shah R.
World Journal of Clinical Oncology,  2014,  цитирований: 113
Targeted delivery of doxorubicin: Drug delivery system based on PAMAM dendrimers
Yabbarov N.G., Posypanova G.A., Vorontsov E.A., Popova O.N., Severin E.S.
Q2 Biochemistry (Moscow),  2013,  цитирований: 22
A new system for targeted delivery of doxorubicin into tumor cells.
Yabbarov N.G., Posypanova G.A., Vorontsov E.A., Obydenny S.I., Severin E.S.
Q1 Journal of Controlled Release,  2013,  цитирований: 43
BRCA mutations in the management of breast cancer: the state of the art
Narod S.A.
Q1 Nature Reviews Clinical Oncology,  2010,  цитирований: 115
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman R.J., Shih I.
Q1 American Journal of Surgical Pathology,  2010,  цитирований: 1119
Метрики

Поделиться

Цитировать
ГОСТ |
Цитировать
ГОСТ Копировать
1. Mollaev M.D. и др. Obtaining and Purification of Recombinant Domain III of Human Alpha-Fetoprotein // Biotekhnologiya. 2021. Т. 37. № 4. С. 32–42.
RIS |
Цитировать
RIS Копировать

TY - JOUR

DO - 10.21519/0234-2758-2021-37-4-32-42

UR - http://dx.doi.org/10.21519/0234-2758-2021-37-4-32-42

TI - Obtaining and Purification of Recombinant Domain III of Human Alpha-Fetoprotein

T2 - Biotekhnologiya

AU - Mollaev, M.D.

AU - Zabolotskii, A.I.

AU - Mazalev, D.A.

AU - Gorokhovets, N.V.

AU - Sokol, M.B.

AU - Mollaeva, M.R.

AU - Fomicheva, M.V.

AU - Pshenichnikova, A.B.

AU - Nikolskaya, E.D.

PY - 2021

PB - National Research Center Kurchatov Institute

SP - 32-42

IS - 4

VL - 37

SN - 2500-2341

SN - 0234-2758

ER -

BibTex |
Цитировать
BibTex Копировать

@article{Mollaev_2021,

doi = {10.21519/0234-2758-2021-37-4-32-42},

url = {https://doi.org/10.21519%2F0234-2758-2021-37-4-32-42},

year = 2021,

publisher = {National Research Center Kurchatov Institute},

volume = {37},

number = {4},

pages = {32--42},

author = {M.D. Mollaev and A.I. Zabolotskii and D.A. Mazalev and N.V. Gorokhovets and M.B. Sokol and M.R. Mollaeva and M.V. Fomicheva and A.B. Pshenichnikova and E.D. Nikolskaya},

title = {Obtaining and Purification of Recombinant Domain {III} of Human Alpha-Fetoprotein},

journal = {Biotekhnologiya}

}

MLA
Цитировать
MLA Копировать
Mollaev, M.D. et al. “Obtaining and Purification of Recombinant Domain III of Human Alpha-Fetoprotein.” Biotekhnologiya 37.4 (2021): 32–42. Crossref. Web.